MD MBA - Oxurion NV Chief Officer

TG4 Stock  EUR 0.28  0.00  0.00%   

Insider

MD MBA is Chief Officer of Oxurion NV
Phone32 1 675 13 10
Webhttps://www.oxurion.com

Oxurion NV Management Efficiency

The company has return on total asset (ROA) of (1.0084) % which means that it has lost $1.0084 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.9415) %, meaning that it generated substantial loss on money invested by shareholders. Oxurion NV's management efficiency ratios could be used to measure how well Oxurion NV manages its routine affairs as well as how well it operates its assets and liabilities.
Oxurion NV has accumulated 8.43 M in total debt. Oxurion NV has a current ratio of 9.34, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Oxurion NV until it has trouble settling it off, either with new capital or with free cash flow. So, Oxurion NV's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oxurion NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oxurion to invest in growth at high rates of return. When we think about Oxurion NV's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

INSIDER Age

Yuji HiyaNishi Nippon Railroad Co
66
Hideaki ShozakiNishi Nippon Railroad Co
64
Katsuhiko MiyataNishi Nippon Railroad Co
67
Kazutoshi ShoyamaNishi Nippon Railroad Co
61
Sunao OkakuNishi Nippon Railroad Co
N/A
Shigeyuki TakasakiNishi Nippon Railroad Co
68
Tetsuya NagasaoNishi Nippon Railroad Co
N/A
Kazuyuki TakeshimaNishi Nippon Railroad Co
75
Koichiro TodaNishi Nippon Railroad Co
N/A
Sumio KuratomiNishi Nippon Railroad Co
70
Oxurion NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium. ThromboGenics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 78 people. Oxurion NV (TG4) is traded on Frankfurt Exchange in Germany and employs 34 people.

Management Performance

Oxurion NV Leadership Team

Elected by the shareholders, the Oxurion NV's board of directors comprises two types of representatives: Oxurion NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oxurion. The board's role is to monitor Oxurion NV's management team and ensure that shareholders' interests are well served. Oxurion NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oxurion NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, Chief Officer
Kathleen Paisley, Chief Officer
Thomas CFA, CFO CEO
Julie Binon, Chief Officer
Wouter Piepers, Global Relations
Michael Dillen, Chief Sec

Oxurion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oxurion NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Oxurion Stock

Oxurion NV financial ratios help investors to determine whether Oxurion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oxurion with respect to the benefits of owning Oxurion NV security.